News Releases

November 30, 2012

Announcement; Launch of 5-HT3 Receptor Antagonist Aloxi_® I.V. infusion bag 0.75mg

September 28, 2012

ZOSYN_®, an Injectable Antibiotic Combination Product Receives an Approval for Peritonitis,
Intra-abdominal Abscess, Cholecystitis, and Cholangitis

September 18, 2012

Clinical Trial (JASPAC 01) of TS-1 for Resected Pancreatic Cancer

August 28, 2012

Results of a Phase II Clinical Trial for the Novel Antitumor Agent TAS-102 Posted on the Electronic Edition of The Lancet Oncology

July 24, 2012

Taiho and Faes Farma (Spain) Enter into a License Agreement on Anti-Allergy Agent

July 11, 2012

Business Partnership regarding Breakthrough Cancer Pain Reliever "OVF"（PDF：58.8 KB）

June 22, 2012

Launch of Histamine H2 Receptor Antagonist PROTECADIN_® OD Tablets
(Orally Disintegrating Tablet)

June 06, 2012

Phase III Clinical Trial (CATS TRIAL) for Non-small-cell Lung Cancer Non-inferiority of TS-1 + Cisplatin Treatment Verified Presented to the American Society of Clinical Oncology (ASCO)

May 31, 2012

Taiho Pharmaceutical Announces the Start of a Global Phase III Clinical Trial in Metastatic Colorectal Cancer with the Novel Antitumor Agent TAS-102

April 16, 2012

Distributor change for Lentinan I.V. Infusion 1mg "Ajinomoto", an anti-tumor agent （PDF：57.5 KB）

April 11, 2012

Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Hong Kong

April 11, 2012

Anti-Cancer Drug Teysuno_® has been launched in the United Kingdom.

March 30, 2012

Termination of co-development of a β3-adrenoceptor agonist （PDF：61.0 KB）

March 21, 2012

Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Thailand

March 21, 2012

Anti-Cancer Drug Teysuno_® has been launched in Sweden, Denmark, Norway and Finland

March 09, 2012

Licensing Agreement Cancelled for NST-141 Agent for Pruritus in Atopic Dermatitis

March 01, 2012

ABRAXANE_® I.V. Infusion 100mg Application
Submitted for Approval of Additional Indications in Japan